

Investor Presentation

January 2024

Internal use only

EBR Systems at a glance

Driven to deliver superior treatment for patients suffering from cardiac rhythm diseases



Developer of the **world's first and only** leadless pacemaker for heart failure



EBR's WiSE® CRT System has **no direct competitors** and is **complementary** to other pacemaker technologies



Positive pivotal trial results de-risk the regulatory pathway and validate the device as safe and highly effective



Clear commercial strategy in place focusing on high-volume procedure sites in the US, minimising execution risk




Significant market opportunity with an initial addressable market of US\$2.6bn and potential for further growth



Funded through initial commercialisation with US\$73.4/A\$107.8m cash in bank as of 31 Dec 2023

Traditional pacemakers are suboptimal

Traditional pacemakers use wires or leads to deliver energy to the heart, which can lead to many problems



Coronary Sinus limits Left Ventricle (LV) lead placement locations



Leads can become a way for pathogens to reach the myocardium



Leads can be associated with phrenic nerve stimulation



Leads can migrate and sometimes fracture



Difficult to place



LV lead must be placed outside the heart to avoid blood clots

EBR has a wireless solution for heart failure patients

EBR's WiSE CRT System is the only wireless device that can deliver cardiac resynchronisation therapy

WiSE CRT System fills the gap

Currently the only leadless solution globally for LV pacing including CRT.

Other wireless pacemakers are too big for LV pacing

This increases the risk of blood clots, restricting their use to right ventricle (RV) and right atrium (RA) pacing only.

Complementary solution

WiSE CRT System can be used in conjunction with wireless RV/RA pacemakers to deliver CRT.

Strong competitive protection

WiSE CRT System is protected by over 97 issued patents globally.

Left ventricle



EBR Systems
WiSE CRT System

Right ventricle/atrium




Medtronic
Micra®



Boston
Scientific
Empower®



Abbott
Aveir®



Dr. Jeffrey Alison, Monash Hospital, Melbourne.

Micra on the left, WiSE CRT device held by tweezers on the right.

Note: Illustrative sizing (not to scale)

Pivotal SOLVE-CRT Study meets all endpoints

Positive results confirm WiSE CRT System as a highly effective treatment option for patients with heart failure

Primary efficacy endpoint met

-16.4%
p = 0.003

Decrease in in left ventricular end systolic volume **vs -9.3% target**, showing improved heart function



Success in high-risk patients

SOLVE-CRT patient pool consists of patients who have failed conventional CRT



Other key data

All data analysed to date shows consistent, positive results in reversing heart failure symptoms and physiology

Primary safety endpoint met

80.9%
p < 0.001

Patients free from type I complications **vs 70% target**



Safety profile comparable to SoC

Other studies using standard of care (SoC) treatment for CRT upgrades have shown 81.3% freedom from device & procedure related complications¹



Other key data





Observed complication rates were higher in early phases and decreased with experience

Note: see "CEO Presentation on SOLVE-CRT Pivotal Trial Top-line Data" ASX release on 22 May 2023

¹ Poole, J. E., et al. (2010). Circulation 122(16): 1553-1561

Randomised sub-analysis supports primary results

The WiSE CRT System demonstrates clinically and statistically significant evidence of reverse remodelling and electrical response within previously untreatable and high-risk patients



Control n = 29, Treatment n = 22

Commercialisation pathway

Positive pivotal trial results and strong track record with the FDA de-risk EBR's regulatory approval process and underpin a clear pathway to commercialisation


1

Confidence in FDA approval process underpinned by positive pivotal trial results and a track record of successful engagement with the FDA resulting in:

- Award of Breakthrough Device Designation
- Approval of pivotal study re-design
- Approval of leadless pacemakers as a co-implant in pivotal study


2

- EBR has submitted four out of five required modules for the PMA submission
- The final module is related to biocompatibility & device verification testing which is currently underway



Favourable US market dynamics

Market dynamics in the US support initial adoption of the WiSE CRT System



Market validation

- Support of Key Opinion Leaders (KOLs)
- Unmet need underscored by FDA Breakthrough Device designation
- Low barrier to transition to become first-line therapy (no direct competitors)

Low hospital adoption barriers

- Low barrier for opening new accounts
- No capital equipment required and reimbursement available post-approval
- Proven and refined implanter training program

Reimbursement & High ASP

- CMS recently updated WiSE specific CTP codes (eg 0515T, 0522T)
- CPT codes already assigned to interim APC codes (eg 5231, 5741)
- Clear pathway to NTAP and TPT reimbursement schemes post FDA approval
- Automatic process to reassign APC codes based on actual claims data
- WiSE CRT System ASP: US\$35,000 – US\$45,000¹

ASP: Average Selling Price; NTAP: New Technology Add-on Payment; TPT: Transitional Passthrough Payment
¹ U.S. pricing with New Technology Add-on Payment (NTAP) post-approval

Initial commercialisation strategy

EBR will leverage its established partnerships and presence in the US to drive initial sales growth, targeting first sales during H1 2025



Clinical trial sites to drive initial sales

- CRT market is concentrated - targeting high-volume CRT procedure sites
- 2025: Targeting US sites that have participated in the SOLVE-CRT trial and other high-volume sites with Key Opinion Leaders (KOLs)
- 2026-2027: Target top 200 to 250 clinical sites, representing >50% US CRT market



Specialist sales force established

- Execution of commercial launch supported by specialised direct sales force to target high volume sites
- SOLVE-CRT team in place with clinical and technical expertise of WiSE CRT System
- Grow initial sales and expand into new areas, targeting 35 sales territories by the end of 2027



Scale manufacturing capability

- Existing manufacturers already in place with capability to scale
- Expand in-house manufacturing facility to meet future demand
- As demand increases, seek to optimise operations to reduce global supply chain risk

Long term growth strategy

Long term growth opportunity targeting new patient groups, indications and geographies



Pursue new indications

Progress clinical studies to expand indications and diversify product applications, opportunity to build a new market as first-line-therapy



Product development

Grow addressable market through product development initiatives including development of a rechargeable battery




Expand internationally

Launch in select OUS¹ markets as regulatory and reimbursement coverage is secured using US market entry as a template for success

¹ OUS: Outside the US

US\$2.6bn initial addressable market

At commercial launch, EBR estimates to have an initial addressable market of ~US\$2.6bn



Totally Leadless CRT is a growth market

The Totally Leadless CRT (TLC) market has the potential to grow by an additional US\$4.2bn

Dual Chamber Leadless Upgrades

WiSE CRT System used in conjunction with the Abbott Aveir dual chamber device, estimated to launch late 2023




\$2.2bn segment TAM

Near term expansion opportunity (3-4 years)

First-line treatment with TLC

WiSE CRT System used in conjunction with any leadless device




\$2.0bn segment TAM

Near term expansion opportunity (~4 years)

Market expansion opportunity

The WiSE CRT System can be expanded for use in other patient groups, indications and geographies, increasing EBR's market opportunity and underpinning future growth



Note: Expanding into any additional clinical indications and/or patient groups may require supporting data from clinical studies, additional regulatory approvals, and establishing payment coverage or reimbursement.

Product development: Rechargeable battery

EBR is developing a new rechargeable battery that will support the WiSE CRT System in becoming a first-line therapy option and treat a broader suite of patients

Commercial benefits

- Drives higher uptake by removing barriers to adoption
- Potential to become a first-line therapy option
- Diversifies applicability of the WiSE CRT System and grows the addressable market

Patient benefits

- Reduces need for future battery replacement surgery
- Recharge interval once per week¹
- 66% reduction in size from current battery

Development status

- Specifications and initial design completed
- Regulatory and commercial timing to be announced as project progresses



EBR's rechargeable battery will charge using a patch and external device to provide non-invasive, wireless charging

Upcoming milestones

EBR continues to achieve significant value catalysts and pave the way to future value creation

Delivered

- ✓ SOLVE-CRT 6 Month follow up completed for final patient in February 2023
- ✓ **Headline data released at Heart Rhythm Society conference**
- ✓ **Positive trial data unlocks second tranche of growth capital facility**
- ✓ Clinical Module for PMA application submitted to the FDA
- ✓ Completed randomized sub study and released positive dataset
- ✓ Randomised data presented at industry conferences including APHRS¹

Near term

- ❑ Publication of manuscript in a peer reviewed medical journal
- ❑ Submit Final PMA Module including transmitter upgrades
- ❑ Additional sub-studies published using SOLVE-CRT dataset
- ❑ Expand manufacturing facility
- ❑ Production of prototype rechargeable batteries

Next steps

- ❑ FDA approval in the US
- ❑ Commercial launch in the US
- ❑ Expand use of WiSE CRT System into new patient groups
- ❑ Initiate ACCESS and TLC studies
- ❑ Drive adoption in US
- ❑ Launch of rechargeable battery

¹ Asia Pacific Heart Rhythm Society

² OUS: Outside the US

Investment highlights

EBR is focused on executing its clear and targeted commercialisation strategy to deliver shareholder value

High value market opportunity



Unique solution

No competition as the WiSE CRT system is complementary to other leadless devices



Large markets

Targeting initial addressable market of US\$2.6bn with expansion opportunity up to US\$9.6bn




Positive results

Safety and efficacy endpoints met for SOLVE-CRT trial and Breakthrough Device Designation granted



Focused strategy

Clear pathway to achieve FDA approval and progress commercialisation activities to achieve first sales



Strong team

Experienced management team with significant clinical development and commercial expertise

Internal use only

Appendix




Patient success story - Richard

EBR has allowed the patient to once again partake in all the activities he enjoyed before his heart failure

Pre heart failure

US Marine and Vietnam war veteran who enjoyed a very active and outgoing lifestyle

“Sport was a very big part of my life. I was an active person.”



Onset of heart failure

Heart failure materially impact the patient's quality of life

- **2014:** Pacemaker implanted due collapsing from a low heart rate.
- **2016:** Developed pacing induced heart failure. Conventional lead-based CRT implanted. Multiple lead failures.
- **2017:** Rapid deterioration: *“I couldn't walk up a flight of stairs. I couldn't work, I couldn't do anything. I was just existing.”*

Post WiSE CRT Implant

Post WiSE CRT implant, the patient has been able to enjoy everything he used to do

“I was energised immediately. I could now take out the bins and walk up a flight of stairs.”

“I was able to resume daily walks and open water swimming. Got stronger and lost 20kg.”

“I'm happy, extremely happy. It's given me my life back!”



Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR’s notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. Such statements are typically identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘anticipates’, ‘intends’ and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results

may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR’s management. EBR’s results are reported under US GAAP. Certain financial data in this presentation is “non-IFRS financial information” under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR’s CHES Depositary Interests (“CDIs”) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.



Contact Us

Company

John McCutcheon
President & CEO
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Jed Pedersen
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com

internal use only